243) myeloma, treatment with BT-GSI decreased tumor burden and prevented the progression |
244) sed to TX20005 had a significantly higher tumor burden compared to saline-treated mi |
245) e mice had a greater absolute decrease in tumor burden than lean mice and a repolari |
246) -liver alanine cycle in zebrafish reduced tumor burden. |
247) In mice challenged with Tsc2-/- tumor cells, CAR T cells substantially and |
248) ivity of LDH produces L-2HG in pancreatic tumor cells, regulating the stemness-diffe |
249) s, implicating complex interactions among tumor cells, stromal cells and immune infi |
250) minished levels of autophagic activity in tumor cells, which might result in transit |
251) sis suggested that NSP3 (SH2D3C) promotes tumor immune evasion via dysfunctional T-c |
252) whether it plays a role in modulating the tumor immune microenvironment is not prope |
253) eutrophils are emerging as one of the key tumor-infiltrating immune cells that influ |
254) Phagocytic resistance plays a key role in tumor-mediated immune escape, so phagocyto |
255) ACTs have been developed and introduced; tumor-infiltrating lymphocytes (TILs) and |
256) ') to analyze the spatial distribution of tumor-infiltrating lymphocytes (TILs) in h |
257) ote an inflammatory state that may modify tumor-infiltrating lymphocytes and tumor-a |
258) " scenario, in which cancer cells deprive tumor-infiltrating lymphocytes of needed g |
259) Results from immunocompetent mouse tumor models further confirm that macropha |
260) ive in potent inhibition of the growth of tumor models including patient-derived xen |
261) hototherapy in vitro and in vivo in mouse tumor models. |
262) or activity in several leukemic and solid tumor models. |
263) ies involving CX-5461 have promising anti-tumor activity in vivo in neuroblastoma, o |
264) Recent data attributed the tumor-promoting activity of high-fat diets |
265) sulting in secondary bile acids that show tumor-promoting activity. |
266) ng M2 macrophage associated proteins, and tumor angiogenesis by enhancing the activa |
267) MicroRNAs (miRNAs) participate in tumor angiogenesis in NSCLC. |
268) ation and migration are critical steps in tumor angiogenesis. |
269) ic T cell immunity and provided effective tumor control and long-term immunological |
270) ed with SRS so as to investigate rates of tumor control and symptomatic improvement. |
271) circulating immune cells is critical for tumor control. |
272) uired resistance and extended survival of tumor-bearing mice treated with SCD inhibi |
273) In this work, tumor-bearing mice were imaged at 7 T to |
274) Moreover, treatment of breast tumor-bearing mice with C108 resulted in a |
275) the most frequent, lethal, and aggressive tumor of the central nervous system in adu |
|